ClinicalTrials.gg
WithdrawnNCT00512863Updated Nov 6, 2007

A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma

A Phase 2 interventional study of Humira (adalimumab) in Asthma, sponsored by Abbott. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2007-11-06.

Sponsored by Abbott · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the efficacy of SC injections of 3 regimens of adalimumab vs. placebo in the change in post-bronchodilator FEV1 from Baseline to Week 16 when used in the treatment of refractory asthma.

02

Conditions studied

  • Asthma

Browse trials for

03

In context

Asthma

4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.

This study's planned enrollment of 272 is above the median of 79 across 3,345 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of asthma, as defined by the American Thoracic Society,31 defined as 1 major and at least 2 minor criteria
  • Actual or documented history of reversible airway obstruction
  • Baseline of 40% - 80% of the predicted for height, age, and sex at Screening, as demonstrated 6 or more hours after a short-acting -agonist and/or 24 or more hours after a long-acting -agonist
  • History of at least 1 asthma exacerbation leading to oral, IV or IM or ER/Urgent Care Center visit or hospitalization within the past year prior to Screening. This asthma exacerbation should not have been within 30 days prior to Screening
  • Adequate cardiac, renal and hepatic function as determined by the principal investigator and demonstrated by Screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits
  • Subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication

Exclusion criteria

Exclusion Criteria:

  • Active lung diseases (e.g., bronchitis, [COPD], interstitial lung disease, pulmonary fibrosis) other than asthma
  • Current treatment for -resistant asthma (e.g., methotrexate [MTX], cyclosporine, gold salts, troleandomycin, immune globulin intravenous [IGIV], mycophenolate mofetil)
  • History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma - in-situ of the cervix.
  • History of listeria, (HIV), chronic or active , an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease or active TB
  • Females who are pregnant or will not discontinue breast-feeding.
  • Subject with a history of drug or alcohol abuse in the last year
  • Subjects with a poorly controlled medical condition.
  • Abnormal, clinically significant screening laboratory and other analyses (including ).
  • Subjects with any prior exposure to Tysabri® (natalizumab)
  • Prior treatment with any TNF antagonist, including adalimumab
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
272 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint is the change from Baseline in post-bronchodilator FEV1 in subjects treated with adalimumab vs. placebo.

    Time frame: Week 16

Secondary outcomes

  1. Proportion of subjects with at least one asthma exacerbation from Baseline to the end of the double-blind period

    Time frame: Week 16

  2. Changes from Baseline in post-bronchodilator FEV1

    Time frame: Time points other thanWeek 16

  3. Change from Baseline in pre-bronchodilator FEV1

  4. Change from Baseline (pre-bronchodilator) in FEV1

    Time frame: 30 minutes postbronchodilator

  5. Change from Baseline in percent predicted FEV1

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 6, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00512863
Lead sponsor
Abbott
First posted
Aug 8, 2007
Start date
Aug 2007
Last update
Nov 6, 2007

Study contacts

Beverly Paperiello
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion